Immunomodulatory Effects of Macrolide Antibiotics – Part 1: Biological Mechanisms

Macrolide antibiotics are well known for their antibacterial and anti-inflammatory properties. This article provides an overview of the biological mechanisms through which macrolides exert this ‘double effect’. Their antibacterial effect consists of the inhibition of bacterial protein synthesis, impaired bacterial biofilm synthesis, and the attenuation of other bacterial virulence factors. Apart from these direct antimicrobial effects, macrolides are known for their modulating effect on many components of the human immune system. By influencing the production of cytokines, they have a dampening effect on the proinflammatory response. Furthermore, the majority of cells involved in the immune response are, in one way or another, influenced when macrolide antibiotics are administered. Having such an obvious effect on the various aspects of the immune system, macrolides seem to be exceptionally suited for the treatment of chronic inflammatory diseases.

[1]  S. Kamihira,et al.  Efficacy of Clarithromycin against Experimentally Induced Pneumonia Caused by Clarithromycin-Resistant Haemophilus influenzae in Mice , 2009, Antimicrobial Agents and Chemotherapy.

[2]  A. Bhowmik,et al.  Improving mucociliary clearance in chronic obstructive pulmonary disease. , 2009, Respiratory medicine.

[3]  E. Chilvers,et al.  Azithromycin therapy for neutrophilic airways disease: myth or magic? , 2009, Thorax.

[4]  T. Sorsa,et al.  Tetracyclines and Chemically Modified Tetracycline-3 (CMT-3) Modulate Cytokine Secretion by Lipopolysaccharide-Stimulated Whole Blood , 2009, Inflammation.

[5]  K. Yanagihara,et al.  Efficacy of azithromycin in the treatment of community-acquired pneumonia, including patients with macrolide-resistant Streptococcus pneumoniae infection. , 2009, Internal medicine.

[6]  Y. Tanizaki,et al.  Effect of Long-Term and Low-Dose Administration of Erythromycin on Proliferation of T Lymphocytes , 2008 .

[7]  T. Tolker-Nielsen,et al.  Effects of Antibiotics on Quorum Sensing in Pseudomonas aeruginosa , 2008, Antimicrobial Agents and Chemotherapy.

[8]  S. Hodge,et al.  Azithromycin improves macrophage phagocytic function and expression of mannose receptor in chronic obstructive pulmonary disease. , 2008, American journal of respiratory and critical care medicine.

[9]  M. Lucchi,et al.  Pharmacokinetics of azithromycin in serum, bronchial washings, alveolar macrophages and lung tissue following a single oral dose of extended or immediate release formulations of azithromycin. , 2008, The Journal of antimicrobial chemotherapy.

[10]  R. Scott,et al.  Clarithromycin targets neutrophilic airway inflammation in refractory asthma. , 2008, American journal of respiratory and critical care medicine.

[11]  Y. Tanizaki,et al.  Effect of long-term and low-dose administration of erythromycin on proliferation of T lymphocytes stimulated with mitogens. , 2008, Journal of chemotherapy.

[12]  M. Parsek,et al.  Subinhibitory Concentrations of Azithromycin Decrease Nontypeable Haemophilus influenzae Biofilm Formation and Diminish Established Biofilms , 2007, Antimicrobial Agents and Chemotherapy.

[13]  D. Healy.  Macrolide immunomodulation of chronic respiratory diseases , 2007, Current infectious disease reports.

[14]  A. Boner,et al.  Azithromycin reduces bronchial hyperresponsiveness and neutrophilic airway inflammation in asthmatic children: a preliminary report. , 2007, Allergy and asthma proceedings.

[15]  S. Kohno,et al.  Differing effects of clarithromycin and azithromycin on cytokine production by murine dendritic cells , 2007, Clinical and experimental immunology.

[16]  K. Tateda,et al.  Suppression of Pseudomonas aeruginosa quorum-sensing systems by macrolides: a promising strategy or an oriental mystery? , 2007, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

[17]  G. Verleden,et al.  Azithromycin reduces airway neutrophilia and interleukin-8 in patients with bronchiolitis obliterans syndrome. , 2006, American journal of respiratory and critical care medicine.

[18]  S. Hodge,et al.  Azithromycin increases phagocytosis of apoptotic bronchial epithelial cells by alveolar macrophages , 2006, European Respiratory Journal.

[19]  R. Geffers,et al.  Quorum-Sensing Antagonistic Activities of Azithromycin in Pseudomonas aeruginosa PAO1: a Global Approach , 2006, Antimicrobial Agents and Chemotherapy.

[20]  T. Gudjonsson,et al.  Novel Effects of Azithromycin on Tight Junction Proteins in Human Airway Epithelia , 2006, Antimicrobial Agents and Chemotherapy.

[21]  D. Touw,et al.  Pharmacokinetics of Azithromycin in Plasma, Blood, Polymorphonuclear Neutrophils and Sputum During Long-Term Therapy in Patients With Cystic Fibrosis , 2006, Therapeutic drug monitoring.

[22]  U. Ozcelik,et al.  Effects of claritromycin on inflammatory parameters and clinical conditions in children with bronchiectasis 1 , 2006, Journal of clinical pharmacy and therapeutics.

[23]  A. Mackay-Sim,et al.  A Double‐Blind, Randomized, Placebo‐Controlled Trial of Macrolide in the Treatment of Chronic Rhinosinusitis , 2006, The Laryngoscope.

[24]  B. Rubin,et al.  Macrolide antibiotics modulate ERK phosphorylation and IL-8 and GM-CSF production by human bronchial epithelial cells. , 2006, American journal of physiology. Lung cellular and molecular physiology.

[25]  G. Nieman,et al.  CHEMICALLY MODIFIED TETRACYCLINE PREVENTS THE DEVELOPMENT OF SEPTIC SHOCK AND ACUTE RESPIRATORY DISTRESS SYNDROME IN A CLINICALLY APPLICABLE PORCINE MODEL , 2005, Shock.

[26]  N. Webster,et al.  Differential effects of three antibiotics on T helper cell cytokine expression. , 2005, The Journal of antimicrobial chemotherapy.

[27]  M. Parnham,et al.  Cellular Uptake and Efflux of Azithromycin, Erythromycin, Clarithromycin, Telithromycin, and Cethromycin , 2005, Antimicrobial Agents and Chemotherapy.

[28]  M. Nasu,et al.  Antibiotic-induced apoptosis in human activated peripheral lymphocytes. , 2005, International journal of antimicrobial agents.

[29]  S. Ōmura,et al.  Macrolides with Promotive Activity of Monocyte to Macrophage Differentiation , 2005, The Journal of Antibiotics.

[30]  Ronald Anderson,et al.  Membrane-stabilizing, anti-inflammatory interactions of macrolides with human neutrophils , 1996, Inflammation.

[31]  G. Schito,et al.  Inhibition of motility ofPseudomonas aeruginosa andProteus mirabilis by subinhibitory concentrations of azithromycin , 1992, European Journal of Clinical Microbiology and Infectious Diseases.

[32]  J. May,et al.  The Disease-Modifying Effects of Twice-Weekly Oral Azithromycin in Patients with Bronchiectasis , 2005, Treatments in respiratory medicine.

[33]  T. Standiford,et al.  Azithromycin blocks neutrophil recruitment in Pseudomonas endobronchial infection. , 2004, American journal of respiratory and critical care medicine.

[34]  J. Tamaoki,et al.  Clinical implications of the immunomodulatory effects of macrolides. , 2004, The American journal of medicine.

[35]  M. Shapiro,et al.  ROLE OF CHEMICALLY MODIFIED TETRACYCLINE ON TNF-α AND MITOGEN-ACTIVATED PROTEIN KINASES IN SEPSIS , 2004, Shock.

[36]  K. Murphy,et al.  Delays in diagnosis of OSAHS. , 2004, Thorax.

[37]  S. Ohno,et al.  Macrolides inhibit epithelial cell-mediated neutrophil survival by modulating granulocyte macrophage colony-stimulating factor release. , 2004, American journal of respiratory cell and molecular biology.

[38]  S. Braman,et al.  Steady-state intrapulmonary concentrations of moxifloxacin, levofloxacin, and azithromycin in older adults. , 2004, Chest.

[39]  J. Tamaoki.  The effects of macrolides on inflammatory cells. , 2004, Chest.

[40]  D. Wozniak,et al.  Effects of subinhibitory concentrations of macrolide antibiotics on Pseudomonas aeruginosa. , 2004, Chest.

[41]  Ronald Anderson,et al.  Roxithromycin, Clarithromycin, and Azithromycin Attenuate the Injurious Effects of Bioactive Phospholipids on Human Respiratory Epithelium in Vitro , 1997, Inflammation.

[42]  R. Wilson,et al.  Prophylactic antibiotic treatment of bronchiectasis with azithromycin. , 2004, Thorax.

[43]  M. Hentzer,et al.  Pharmacological inhibition of quorum sensing for the treatment of chronic bacterial infections. , 2003, The Journal of clinical investigation.

[44]  G. Tipoe,et al.  Effects of erythromycin on Pseudomonas aeruginosa adherence to collagen and morphology in vitro , 2003, European Respiratory Journal.

[45]  M. Klepser,et al.  Influence of Macrolide Susceptibility on Efficacies of Clarithromycin and Azithromycin against Streptococcus pneumoniae in a Murine Lung Infection Model , 2003, Antimicrobial Agents and Chemotherapy.

[46]  K. Matsushima,et al.  Fourteen-Member Macrolides Promote the Phosphatidylserine Receptor-Dependent Phagocytosis of Apoptotic Neutrophils by Alveolar Macrophages , 2003, Antimicrobial Agents and Chemotherapy.

[47]  M. Rosenthal,et al.  Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial , 2002, The Lancet.

[48]  M. Parnham,et al.  Azithromycin modulates neutrophil function and circulating inflammatory mediators in healthy human subjects. , 2002, European journal of pharmacology.

[49]  E. Tagaya,et al.  Effect of a short course of clarithromycin therapy on sputum production in patients with chronic airway hypersecretion. , 2002, Chest.

[50]  Richard J Martin,et al.  Mycoplasma pneumoniae and Chlamydia pneumoniae in asthma: effect of clarithromycin. , 2002, Chest.

[51]  S. Lindberg,et al.  One-Year Low-Dose Erythromycin Treatment of Persistent Chronic Sinusitis after Sinus Surgery: Clinical Outcome and Effects on Mucociliary Parameters and Nasal Nitric Oxide , 2002, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

[52]  P. Cole,et al.  The Effect of Erythromycin on Mucociliary Transportability and Rheology of Cystic Fibrosis and Bronchiectasis Sputum , 2001, Respiration.

[53]  K. Asano,et al.  Modulation of Th2 type cytokine production from human peripheral blood leukocytes by a macrolide antibiotic, roxithromycin, in vitro. , 2001, International immunopharmacology.

[54]  K. Tateda,et al.  Azithromycin Inhibits Quorum Sensing in Pseudomonas aeruginosa , 2001, Antimicrobial Agents and Chemotherapy.

[55]  D. Griffith,et al.  The effect of azithromycin and clarithromycin on ex vivo interleukin-8 (IL-8) release from whole blood and IL-8 production by human alveolar macrophages. , 2001, The Journal of antimicrobial chemotherapy.

[56]  B. Tümmler,et al.  Buccal Adherence of Pseudomonas aeruginosa in Patients with Cystic Fibrosis under Long-Term Therapy with Azithromycin , 2001, Infection.

[57]  T. Hasegawa,et al.  Effect of Subinhibitory Concentrations of Macrolides on Expression of Flagellin in Pseudomonas aeruginosa and Proteus mirabilis , 2000, Antimicrobial Agents and Chemotherapy.

[58]  H. Ceri,et al.  Apoptosis, oxidative metabolism and interleukin-8 production in human neutrophils exposed to azithromycin: effects of Streptococcus pneumoniae. , 2000, The Journal of antimicrobial chemotherapy.

[59]  H. Saito,et al.  Macrolide Treatment Decreased the Size of Nasal Polyps and IL-8 Levels in Nasal Lavage , 2000, American journal of rhinology.

[60]  S. Ōmura,et al.  Erythromycin suppresses nuclear factor-kappaB and activator protein-1 activation in human bronchial epithelial cells. , 2000, Biochemical and biophysical research communications.

[61]  M. Aoyagi,et al.  Effects of erythromycin on human peripheral neutrophil apoptosis , 1999, Rhinology.

[62]  T. Sorsa,et al.  MMP Inhibition by Chemically Modified Tetracycline‐3 (CMT‐3) in Equine Pulmonary Epithelial Lining Fluid , 1999, Annals of the New York Academy of Sciences.

[63]  M. Luyckx,et al.  Time and concentration dependent influence of dirithromycin on neutrophils oxidative burst. , 1999, The Journal of antibiotics.

[64]  Wai Lam,et al.  A pilot study of low-dose erythromycin in bronchiectasis. , 1999, The European respiratory journal.

[65]  A. Bryskier,et al.  Interactions between HMR 3647, a New Ketolide, and Human Polymorphonuclear Neutrophils , 1998, Antimicrobial Agents and Chemotherapy.

[66]  M. Yanagisawa,et al.  Erythromycin and clarithromycin attenuate cytokine-induced endothelin-1 expression in human bronchial epithelial cells. , 1998, The European respiratory journal.

[67]  S. Kudoh,et al.  Improvement of survival in patients with diffuse panbronchiolitis treated with low-dose erythromycin. , 1998, American journal of respiratory and critical care medicine.

[68]  M. Nasu,et al.  The in vitro Effect of Macrolides on the Interaction of Human Polymorphonuclear Leukocytes with Pseudomonas aeruginosa in Biofilm , 1998, Chemotherapy.

[69]  T. Takasaka,et al.  Effects of long-term low-dose macrolide administration on neutrophil recruitment and IL-8 in the nasal discharge of chronic sinusitis patients. , 1997, The Tohoku journal of experimental medicine.

[70]  B. Rubin,et al.  Effect of clarithromycin on nasal mucus properties in healthy subjects and in patients with purulent rhinitis. , 1997, American journal of respiratory and critical care medicine.

[71]  P. Black.  Anti-inflammatory effects of macrolide antibiotics. , 1997, The European respiratory journal.

[72]  T. Fujii,et al.  Phenotypic characterization of T cells in bronchoalveolar lavage fluid (BALF) and peripheral blood of patients with diffuse panbronchiolitis; the importance of cytotoxic T cells , 1997, Clinical and experimental immunology.

[73]  E. Tagaya,et al.  Effects of roxithromycin and erythromycin on interleukin 8-induced neutrophil recruitment and goblet cell secretion in guinea pig tracheas , 1996, Antimicrobial agents and chemotherapy.

[74]  S. Kohno,et al.  Interleukin 1 beta, tumor necrosis factor alpha, and interleukin 8 in bronchoalveolar lavage fluid of patients with diffuse panbronchiolitis: a potential mechanism of macrolide therapy. , 1996, Respiration; international review of thoracic diseases.

[75]  J. Fujita,et al.  Effect of Macrolide Antibiotics on Macrophage Functions , 1996, Microbiology and immunology.

[76]  M. Labro,et al.  Comparison of various macrolides on stimulation of human neutrophil degranulation in vitro. , 1996, The Journal of antimicrobial chemotherapy.

[77]  M. Nasu,et al.  The influence of azithromycin on the biofilm formation of Pseudomonas aeruginosa in vitro. , 1996, Chemotherapy.

[78]  M. Hashiba,et al.  Inhibitory activity of clarithromycin on biofilm synthesis with Pseudomonas aeruginosa. , 1996, Acta oto-laryngologica. Supplementum.

[79]  T. Fujii,et al.  Long term effect of erythromycin therapy in patients with chronic Pseudomonas aeruginosa infection. , 1995, Thorax.

[80]  R. Davies,et al.  Effect of erythromycin on Haemophilus influenzae endotoxin-induced release of IL-6, IL-8 and sICAM-1 by cultured human bronchial epithelial cells. , 1995, The European respiratory journal.

[81]  H. Mukae,et al.  Increase in activated CD8+ cells in bronchoalveolar lavage fluid in patients with diffuse panbronchiolitis. , 1995, American journal of respiratory and critical care medicine.

[82]  K. Chida,et al.  Effect of 14-membered ring macrolide therapy on chronic respiratory tract infections and polymorphonuclear leukocyte activity. , 1995, Internal medicine.

[83]  K. Aoshiba,et al.  Erythromycin shortens neutrophil survival by accelerating apoptosis , 1995, Antimicrobial agents and chemotherapy.

[84]  M. Nasu,et al.  In-vitro effects of antimicrobial agents on Pseudomonas aeruginosa biofilm formation. , 1994, The Journal of antimicrobial chemotherapy.

[85]  T. Zimmermann,et al.  Distribution of orally administered azithromycin in various blood compartments. , 1994, International journal of clinical pharmacology and therapeutics.

[86]  S. Kohno,et al.  Comparative in vitro exoenzyme-suppressing activities of azithromycin and other macrolide antibiotics against Pseudomonas aeruginosa , 1994, Antimicrobial Agents and Chemotherapy.

[87]  N. Keicho,et al.  Erythromycin promotes monocyte to macrophage differentiation. , 1994, The Journal of antibiotics.

[88]  T. Yokota,et al.  Interaction between clarithromycin and biofilms formed by Staphylococcus epidermidis , 1994, Antimicrobial Agents and Chemotherapy.

[89]  N. Keicho,et al.  Antilymphocytic activity of erythromycin distinct from that of FK506 or cyclosporin A. , 1993, The Journal of antibiotics.

[90]  J. Tomažič,et al.  In vivo administration of azithromycin affects lymphocyte activity in vitro , 1993, Antimicrobial Agents and Chemotherapy.

[91]  C. Haslett,et al.  Impairment of function in aging neutrophils is associated with apoptosis. , 1993, Journal of immunology.

[92]  C. Guzmán,et al.  Inhibition of Pseudomonas aeruginosa virulence factors by subinhibitory concentrations of azithromycin and other macrolide antibiotics. , 1993, The Journal of antimicrobial chemotherapy.

[93]  M. Kaku,et al.  Potential effects of erythromycin on host defense systems and virulence of Pseudomonas aeruginosa , 1992, Antimicrobial Agents and Chemotherapy.

[94]  L. Golub,et al.  Host modulation with tetracyclines and their chemically modified analogues. , 1992, Current opinion in dentistry.

[95]  N. Narita,et al.  Suppression of virulence factors of Pseudomonas aeruginosa by erythromycin. , 1991, Journal of Antimicrobial Chemotherapy.

[96]  Eriko Yamaguchi,et al.  Long-term low-dose administration of erythromycin to patients with diffuse panbronchiolitis. , 1991, Respiration; international review of thoracic diseases.

[97]  T. Yamasaki.  [Adherence of Pseudomonas aeruginosa to mouse tracheal epithelium--the effect of antimicrobial agents]. , 1990, Kansenshogaku zasshi. The Journal of the Japanese Association for Infectious Diseases.

[98]  W. L. Hand,et al.  Antibiotic inhibition of the respiratory burst response in human polymorphonuclear leukocytes , 1990, Antimicrobial Agents and Chemotherapy.

[99]  J. El Benna,et al.  Comparison of the in-vitro effect of several macrolides on the oxidative burst of human neutrophils. , 1989, The Journal of antimicrobial chemotherapy.

[100]  S. Kudoh,et al.  [Clinical effects of low-dose long-term erythromycin chemotherapy on diffuse panbronchiolitis]. , 1987, Nihon Kyobu Shikkan Gakkai zasshi.